Skip to main content

Table 2 Characteristics of the analyzed studies on endometrial transcriptomics for infertile women in natural and stimulated Cycle

From: 15 years of transcriptomic analysis on endometrial receptivity: what have we learnt?

First author and reference

Participants population

N of patients

Age

Comparative

Region

Array

First sample (day, n)

Second sample (day, n)

N of genes up-regulated

N of genes down regulated

Infertile women

 Natural cycles

  Koler et al. [41]

women with unexplained infertility + fertile women

32

19-40

Infertile vs fertile

Europe

Array-Ready Oligo SetTM for the Human Genome Version 3.0 (Operon)

cd21

Infertile women (n = 4)

fertile women (n = 12

25

288

  Altmae et al. [31]

women with unexplained infertility

Infertile women (n = 4)

Fertile women (n = 4)

30.5+4.0

31.8+3.8

Infertile vs fertile

Europe

Whole Human Genome Oligo Microarray (Agilent Technologies)

LH +7

Infertile women (n = 4)

fertile women (n = 5)

145

115

  Koot et al. [34]

women experiencing RIF

115

26-39

Infertile vs fertile

Europe

Human whole genome gene expression microarrays V2 (Agilent)

mid-luteal phase

n = 115

303 genes predictive of RIF

303 genes predictive of RIF

 Stimulated cycles

  Liu et al. [25]

Infertile women with normal menstrual cycles

47

26 -38

NC vs CCOS

Hong Kong

HG_U133A (Affymetrix)

LH+7

n = 5

hCG+7

n = 8

244

159

  Ruiz-Alonso et al. [36]

Patients with repeated implantation failure

110

23-51

RIF vs controls

pWOI/Pwoi delayed/pWOI advanced

Europe

homemade ERA

P+5

LH+7

-

-

  Altmae et al. [19]

Patients with repeated implantation failure

15

30.2 ± 4.3

Infertile vs fertile

Europe

Whole Human Genome Oligo Microarray (Agilent Technologies

LH+7 (n = 5)

P+6 (n = 5)

443

446

  Haouzi et al. [33]

Oocyte-donation recipient patients

RIF patients

39

31-50

NC vs HRT hormone replacement therapy

Europe

HGU133 plus 2.0 (Affymetrix)

LH+7 (n = 7)

P+5 (n = 7)

1814

477

  1. Abbreviations: EP Early-proliferative, ES Early-Secretory, Ag Agonist, Atg Antagonist, LH+ LH surge + days, NC Natural cycle, COH Controlled ovarian hyperstimulation, MS mid-secretory, CCOS Controlled ovarian stimulation, PP proliferative phase, P+ Progesterone+ days, HRT hormone replacement therapy, pWO personalised window of implantation